Antibacterial activity of mometasone furoate.
OBJECTIVE
To test the antibacterial properties of the topical corticoid mometasone furoate, which is used as a nasal spray.


METHODS
The activity of mometasone (0.01%, 0.1%, and 0.5%) in buffer solution against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Streptococcus pyogenes, and Streptococcus milleri was tested by quantitative killing assays.


METHODS
In vitro study.


METHODS
Reduction of viable bacteria and fungi in quantitative killing assays.


RESULTS
Mometasone (0.5%) reduced viable counts of S pyogenes and S milleri by 99.99% and 99.00%, respectively, after 24 hours of incubation, whereas colony-forming units (CFUs) of S aureus, P aeruginosa, and E coli were not affected by the corticoid. Mometasone (0.1%) caused a decrease in CFUs of S pyogenes of 99.90% to 99.99%, while it led to a 99.00% reduction in CFUs of S milleri, but only if low bacterial counts of 1 x 10(4) CFUs/mL were incubated. By contrast, the use of mometasone at a low concentration (0.01%) demonstrated an increase in CFUs of S milleri if the baseline bacterial count was low (1 x 10(4) CFUs/mL).


CONCLUSIONS
Mometasone demonstrates antimicrobial activity against streptococci.
Neher
Andreas
A
Department of Otorhinolaryngology, Innsbruck Medical University, Anichstr 35, Innsbruck, Austria. Andreas.Neher@i-med.ac.at
Gstöttner
Michaela
M
Scholtz
Arne
A
Nagl
Markus
M
D000281:Administration, Intranasal; D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D004926:Escherichia coli / Q000187:drug effects*; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D000068656:Mometasone Furoate; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy* / Q000382:microbiology; D011244:Pregnadienediols / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013211:Staphylococcus aureus / Q000187:drug effects; D034364:Streptococcus milleri Group / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
D000336:Aerosols; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate